News >

CAR T-Cell Approvals Leading Landscape of Hematologic Cancers

Angelica Welch
Published: Friday, Oct 20, 2017

Andre Goy, MD

Andre Goy, MD
Adding to the excitement of the FDA’s August 2017 monumental approval of tisagenlecleucel (Kymriah) in acute lymphoblastic leukemia (ALL), the agency recently approved the CD19-directed chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adults with relapsed/refractory non-Hodgkin lymphoma (NHL).

, Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, Hackensack Medical Center, discussed the recent success with CAR T-cell therapy, and what is on the horizon for this therapeutic option across hematologic malignancies.

OncLive: This year we had our first approved CAR T-cell therapy, and, more recently, another. Can you discuss what this means for the field?

Goy: The approval of tisagenlecleucel as the first CAR T cell approved in patients aged 13 to 25 years with relapsed/refractory ALL is a milestone in medicine well beyond oncology. This is the first approval of a live-cell, gene-modified therapy in the United States, and [is] a game changer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication